NO964008L - Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler - Google Patents
Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midlerInfo
- Publication number
- NO964008L NO964008L NO964008A NO964008A NO964008L NO 964008 L NO964008 L NO 964008L NO 964008 A NO964008 A NO 964008A NO 964008 A NO964008 A NO 964008A NO 964008 L NO964008 L NO 964008L
- Authority
- NO
- Norway
- Prior art keywords
- aryl
- lower alkyl
- substituted
- alkyl
- coor6
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/30—Preparation of optical isomers
- C07C227/32—Preparation of optical isomers by stereospecific synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21849894A | 1994-03-25 | 1994-03-25 | |
PCT/US1995/003196 WO1995026334A1 (en) | 1994-03-25 | 1995-03-22 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NO964008D0 NO964008D0 (no) | 1996-09-24 |
NO964008L true NO964008L (no) | 1996-11-22 |
Family
ID=22815366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO964008A NO964008L (no) | 1994-03-25 | 1996-09-24 | Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler |
Country Status (20)
Country | Link |
---|---|
US (2) | US5627176A (ko) |
EP (1) | EP0751934B1 (ko) |
JP (1) | JP3524927B2 (ko) |
KR (1) | KR100338171B1 (ko) |
CN (1) | CN1144522A (ko) |
AT (1) | ATE183738T1 (ko) |
AU (1) | AU686361B2 (ko) |
CA (1) | CA2186364C (ko) |
CZ (1) | CZ281596A3 (ko) |
DE (1) | DE69511687T2 (ko) |
DK (1) | DK0751934T3 (ko) |
ES (1) | ES2135050T3 (ko) |
FI (1) | FI963817A0 (ko) |
GR (1) | GR3031105T3 (ko) |
HU (1) | HU221309B1 (ko) |
NO (1) | NO964008L (ko) |
NZ (1) | NZ283528A (ko) |
PL (1) | PL316431A1 (ko) |
SK (1) | SK119796A3 (ko) |
WO (1) | WO1995026334A1 (ko) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
AU7472896A (en) * | 1995-11-02 | 1997-05-22 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon |
US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
AU4343500A (en) | 1999-04-16 | 2000-11-02 | Schering Corporation | Use of azetidinone compounds |
US6584357B1 (en) * | 2000-10-17 | 2003-06-24 | Sony Corporation | Method and system for forming an acoustic signal from neural timing difference data |
DE60106489T2 (de) * | 2000-12-20 | 2005-10-13 | Schering Corp. | Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
CA2434504A1 (en) * | 2001-01-26 | 2002-08-01 | Teddy Kosoglou | Combinations of sterol absorption inhibitor(s) with blood modifiers for treating vascular conditions |
US7417039B2 (en) * | 2001-01-26 | 2008-08-26 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
AU2005246926B2 (en) * | 2001-01-26 | 2008-02-28 | Merck Sharp & Dohme Corp. | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
TWI337083B (en) * | 2001-01-26 | 2011-02-11 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
US7071181B2 (en) * | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
CA2442219C (en) | 2001-03-28 | 2007-09-11 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
US7056906B2 (en) * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
SI1429756T1 (sl) * | 2001-09-21 | 2007-02-28 | Schering Corp | Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola |
ATE345793T1 (de) * | 2001-09-21 | 2006-12-15 | Schering Corp | Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption |
US20030204096A1 (en) * | 2002-03-25 | 2003-10-30 | Schering Corporation | Enantioselective synthesis of azetidinone intermediate compounds |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US7135556B2 (en) * | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
ES2318274T3 (es) * | 2003-03-07 | 2009-05-01 | Schering Corporation | Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia. |
ATE406364T1 (de) * | 2003-03-07 | 2008-09-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
US20050096307A1 (en) * | 2003-11-05 | 2005-05-05 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
CN100471835C (zh) * | 2003-12-23 | 2009-03-25 | 默克公司 | 抗高胆固醇血症化合物 |
BRPI0418004A (pt) | 2003-12-23 | 2007-04-17 | Astrazeneca Ab | composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis |
JP4590417B2 (ja) * | 2004-01-16 | 2010-12-01 | メルク・シャープ・エンド・ドーム・コーポレイション | Npc1l1(npc3)およびこのリガンドの同定方法 |
EP1807070A1 (en) * | 2004-09-29 | 2007-07-18 | Schering Corporation | Combinations of substituted azetidinones and cb1 antagonists |
NZ555320A (en) | 2004-12-03 | 2010-11-26 | Schering Corp | Substituted piperazines as CB1 antagonists |
ES2337727T3 (es) * | 2005-06-20 | 2010-04-28 | Schering Corporation | Derivados de piperidina utiles como antagonistas de histamina h3. |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
WO2007100807A2 (en) | 2006-02-24 | 2007-09-07 | Schering Corporation | Npc1l1 orthologues |
CN101394837A (zh) * | 2006-03-06 | 2009-03-25 | 特瓦制药工业有限公司 | 折替米贝组合物 |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
WO2008108486A1 (ja) | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-ビアリールアゼチジノン誘導体 |
US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
US20090047716A1 (en) * | 2007-06-07 | 2009-02-19 | Nurit Perlman | Reduction processes for the preparation of ezetimibe |
EP2548874A3 (en) * | 2007-06-28 | 2013-05-15 | Intervet International B.V. | Substituted piperazines as CB1 antagonists |
JP2010531874A (ja) * | 2007-06-28 | 2010-09-30 | インターベット インターナショナル ベー. フェー. | Cb1アンタゴニストとしての置換ピペラジン |
US20090093627A1 (en) * | 2007-08-30 | 2009-04-09 | Lorand Szabo | Process for preparing intermediates of ezetimibe by microbial reduction |
CN101200443B (zh) * | 2007-10-17 | 2011-06-29 | 中国药科大学 | 氮杂环丁酮衍生物、其制备方法及含有它们的药物组合 |
CA2754384A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
CN101993403B (zh) * | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
MX365046B (es) | 2012-05-01 | 2019-05-17 | Althera Life Sciencies Llc | Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares. |
JP5969958B2 (ja) * | 2013-06-27 | 2016-08-17 | 国立大学法人お茶の水女子大学 | 光学活性含フッ素アミノ酸類の製造方法 |
CN105294426B (zh) | 2014-06-09 | 2019-05-14 | 浙江海正药业股份有限公司 | 氮杂环丁酮化合物制备方法及其中间体 |
CN104860980B (zh) * | 2015-04-23 | 2018-06-19 | 上海弈柯莱生物医药科技有限公司 | 一种用于合成依折麦布的中间体及其制备方法和应用 |
MX2019009213A (es) | 2017-01-23 | 2019-09-27 | Dong Wha Pharm Co Ltd | Formulación compleja que comprende inhibidor de la hmg-coa reductasa y clopidogrel. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
US4803266A (en) * | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
NZ228600A (en) * | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
JPH02268144A (ja) * | 1989-04-11 | 1990-11-01 | Ube Ind Ltd | β―アミノエステルの製造法 |
US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5120729A (en) * | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
HUT67341A (en) * | 1991-07-23 | 1995-03-28 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof |
-
1995
- 1995-03-13 US US08/403,081 patent/US5627176A/en not_active Expired - Lifetime
- 1995-03-22 DE DE69511687T patent/DE69511687T2/de not_active Expired - Lifetime
- 1995-03-22 CA CA002186364A patent/CA2186364C/en not_active Expired - Fee Related
- 1995-03-22 DK DK95914719T patent/DK0751934T3/da active
- 1995-03-22 EP EP95914719A patent/EP0751934B1/en not_active Expired - Lifetime
- 1995-03-22 CZ CZ962815A patent/CZ281596A3/cs unknown
- 1995-03-22 PL PL95316431A patent/PL316431A1/xx unknown
- 1995-03-22 NZ NZ283528A patent/NZ283528A/en not_active IP Right Cessation
- 1995-03-22 JP JP52518495A patent/JP3524927B2/ja not_active Expired - Fee Related
- 1995-03-22 HU HU9602616A patent/HU221309B1/hu not_active IP Right Cessation
- 1995-03-22 CN CN95192277A patent/CN1144522A/zh active Pending
- 1995-03-22 ES ES95914719T patent/ES2135050T3/es not_active Expired - Lifetime
- 1995-03-22 AT AT95914719T patent/ATE183738T1/de not_active IP Right Cessation
- 1995-03-22 WO PCT/US1995/003196 patent/WO1995026334A1/en active IP Right Grant
- 1995-03-22 AU AU21596/95A patent/AU686361B2/en not_active Ceased
- 1995-03-22 KR KR1019960705349A patent/KR100338171B1/ko not_active IP Right Cessation
- 1995-03-22 SK SK1197-96A patent/SK119796A3/sk unknown
- 1995-05-18 US US08/444,167 patent/US5688990A/en not_active Expired - Lifetime
-
1996
- 1996-09-24 NO NO964008A patent/NO964008L/no unknown
- 1996-09-25 FI FI963817A patent/FI963817A0/fi unknown
-
1999
- 1999-08-27 GR GR990402188T patent/GR3031105T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
KR970702246A (ko) | 1997-05-13 |
EP0751934A1 (en) | 1997-01-08 |
DK0751934T3 (da) | 1999-12-13 |
WO1995026334A1 (en) | 1995-10-05 |
JPH09510970A (ja) | 1997-11-04 |
CA2186364A1 (en) | 1995-10-05 |
AU2159695A (en) | 1995-10-17 |
DE69511687T2 (de) | 2000-03-16 |
CZ281596A3 (en) | 1997-05-14 |
US5627176A (en) | 1997-05-06 |
FI963817A (fi) | 1996-09-25 |
HUT74887A (en) | 1997-02-28 |
AU686361B2 (en) | 1998-02-05 |
CA2186364C (en) | 2008-12-30 |
DE69511687D1 (de) | 1999-09-30 |
ATE183738T1 (de) | 1999-09-15 |
HU9602616D0 (en) | 1996-11-28 |
GR3031105T3 (en) | 1999-12-31 |
SK119796A3 (en) | 1997-05-07 |
NZ283528A (en) | 1997-12-19 |
JP3524927B2 (ja) | 2004-05-10 |
US5688990A (en) | 1997-11-18 |
CN1144522A (zh) | 1997-03-05 |
MX9604030A (es) | 1997-09-30 |
PL316431A1 (en) | 1997-01-06 |
KR100338171B1 (ko) | 2002-11-23 |
EP0751934B1 (en) | 1999-08-25 |
FI963817A0 (fi) | 1996-09-25 |
HU221309B1 (en) | 2002-09-28 |
NO964008D0 (no) | 1996-09-24 |
ES2135050T3 (es) | 1999-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO964008L (no) | Substituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler | |
NO972272D0 (no) | Svovelsubstituerte azetidinonforbindelser som er anvendbare som hypokolesterolemiske midler | |
TW427974B (en) | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents | |
ES2266459T3 (es) | Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia. | |
AR035739A1 (es) | Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares | |
JP4351842B2 (ja) | 低コレステロール血症剤として有用な糖置換2−アゼチジノン | |
RU2203274C2 (ru) | Спироциклические ингибиторы металлопротеаз | |
IL133623A0 (en) | Antithrombotic agents | |
IL133627A0 (en) | Antithrombotic agents | |
MX9606319A (es) | Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos. | |
HUT75865A (en) | Tropane-2-aldoxime derivatives pharmaceutical compositions containing them, process for producing them and their use | |
AU5125798A (en) | Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use | |
RU2005124679A (ru) | Новые соединения, ингибирующие фактор viia |